Ann: Half-Year Results Presentation - 31 December 2014, page-22

IMO the point is missed - paying that amount because market sees no potential with the "one product line" the company has and the generics appearing to be taking over. Company IMO has not progressed much over the last few years as far as additional products/revenue streams goes which may be perceived as a weakness. so the cynical may suggest that they are preserving funds to fund day to day operations rather than cost cutting - have you spared a thought to what 1) the PR department is doing, 2) what the R&D have done in the past few years notwithstanding they are paid above market (refer previous ACR ANN where this was mentioned), 3) the Helix issue still unresolved. so as you can see there are other issues the market not sure about.

anyhow been here b4 but IMO any uplift in SP will be less than b4 until some "good" news is announced. all IMO so DYOR and form your own opinions.